900 Middlefield Road
4th Floor
Redwood City, CA 94063
United States
650 980 9099
https://biomeafusion.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 103
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Thomas Andrew Butler | Co-Founder, Chairman & CEO | 950.41k | N/A | 1981 |
Mr. Ramses M. Erdtmann | Co-Founder, President, COO & Director | N/A | N/A | 1963 |
Mr. Franco Valle | CFO & Principal Accounting Officer | 673.66k | N/A | 1981 |
Caroline Perez- Dupont | Senior Vice President of Contracts | N/A | N/A | N/A |
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Biomea Fusion, Inc.’s ISS governance QualityScore as of 1 May 2024 is 9. The pillar scores are Audit: 6; Board: 9; Shareholder rights: 8; Compensation: 9.